Differential 5-Year Brain Atrophy Rates in Cognitively Declining and Stable \u3cem\u3eAPOE\u3c/em\u3e-Ε4 Elders by Kelly, Dana A. et al.
Marquette University
e-Publications@Marquette
Psychology Faculty Research and Publications Psychology, Department of
9-1-2018
Differential 5-Year Brain Atrophy Rates in











See next page for additional authors
Accepted version. Neuropsychology, Vol. 32, No. 6 (2018): 647-653. DOI. © 2018 American
Psychological Association. Used with permission.
Authors
Dana A. Kelly, Michael Seidenberg, Katherine Reiter, Kristy A. Nielson, John L. Woodard, J. Carson Smith,
Sally Durgerian, and Stephen M. Rao





Psychology Faculty Research and Publications/College of Arts and Sciences 
 
This paper is NOT THE PUBLISHED VERSION; but the author’s final, peer-reviewed manuscript. The 
published version may be accessed by following the link in th citation below. 
 
 
Neuropsychology, Vol. 32, No. 6 (2018): 647-653. DOI. This article is © American Psychological 
Association and permission has been granted for this version to appear in e-Publications@Marquette. 
American Psychological Association does not grant permission for this article to be further 
copied/distributed or hosted elsewhere without the express permission from American Psychological 
Association.  
Differential 5-Year Brain Atrophy Rates in 
Cognitively Declining and Stable APOE-Ε4 
Elders 
 
Dana A. Kelly 
Department of Psychology, Rosalind Franklin University of Medicine and Science 
Michael Seidenberg 
Department of Psychology, Rosalind Franklin University of Medicine and Science 
Katherine Reiter 
Department of Psychology, Marquette University 
Kristy A. Nielson 
Department of Psychology, Marquette University 
John L. Woodard 
Department of Psychology, Wayne State University 
J. Carson Smith 
Department of Kinesiology, School of Public Health, University of Maryland 
Sally Durgerian 
BrainDataDriven LLC, Milwaukee, Wisconsin 
Stephen M. Rao 
Schey Center for Cognitive Neuroimaging, Cleveland Clinic, Cleveland, Ohio; 
Abstract 
Objective: The apolipoprotein E (APOE) ε4 allele is the most important genetic risk factor for late-onset 
Alzheimer’s disease. Many ε4 carriers, however, never develop Alzheimer’s disease. The purpose of this study is 
to characterize the variability in phenotypic expression of the ε4 allele, as measured by the longitudinal 
trajectory of cognitive test scores and MRI brain volumes, in cognitively intact elders. Method: Healthy older 
adults, ages 65–85, participated in a 5-year longitudinal study that included structural MRI and cognitive testing 
administered at baseline and at 1.5 and 5 years postenrollment. Participants included 22 ε4 noncarriers, 15 ε4 
carriers who experienced a decline in cognition over the 5-year interval, and 11 ε4 carriers who remained 
cognitively stable. Results: No baseline cognitive or volumetric group differences were observed. Compared to 
noncarriers, declining ε4 carriers had significantly greater rates of atrophy in left (p = .001, Cohen’s d = .691) and 
right (p = .003, d = .622) cortical gray matter, left (p = .003, d = .625) and right (p = .020, d = .492) hippocampi, 
and greater expansion of the right inferior lateral ventricle (p < .001, d = .751) over 5 years. Conclusions: This 
study illustrates the variability in phenotypic expression of the ε4 allele related to neurodegeneration. 
Specifically, only those individuals who exhibited longitudinal declines in cognitive function experienced 
concomitant changes in brain volume. Future research is needed to better understand the biological and 
lifestyle factors that may influence the expression of the ε4 allele. (PsycINFO Database Record (c) 2018 APA, all 
rights reserved) 
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The apolipoprotein E (APOE) ε4 allele confers an increased risk for developing late-onset Alzheimer’s disease (LOAD; Corder 
et al., 1993; Liu et al., 2015; Smith et al., 1998). APOE ε4 homozygotes experience a 13- to 15-fold increased chance of being 
diagnosed during their lifetime, whereas ε4 heterozygotes experience a 3-fold increase (Ashford, 2004). Even prior to the 
diagnosis of mild cognitive impairment or LOAD, older adults possessing an APOE ε4 allele experience greater cognitive 
deficits in episodic memory, executive functioning, perceptual speed, and global cognition than noncarriers (Wisdom, 
Callahan, & Hawkins, 2011). Longitudinal studies of cognitively intact, older ε4 carriers and noncarriers demonstrate greater 
cognitive decline in the former group over time (Pietrzak et al., 2015; Rao et al., 2015; Woodard et al., 2010). Likewise, 
longitudinal structural MRI studies indicate significantly different trajectories of neurodegeneration in the hippocampus and 
ventricles between cognitively intact, older ε4 carriers and noncarriers (Lu et al., 2011; Reiter et al., 2016; Roussotte et al., 
2014). 
 
Such studies tend to treat ε4 carriers as a homogeneous group. Yet, many cognitively intact elders with the ε4 allele never 
develop LOAD during a normal life span (Relkin, Kwon, Tsai, & Gandy, 1996). A lack of uniform deterioration among ε4 
carriers may be explained by biological (e.g., APOE ε4 zygosity, comorbid medical illnesses) and/or lifestyle (e.g., education, 
physical activity) factors that likely modulate the impact of the ε4 allele on the development of Alzheimer’s disease 
(AD; Schwartz, Rapkin, & Healy, 2016; Small, Rosnick, Fratiglioni, & Bäckman, 2004; Smith et al., 2014). 
 
The primary purpose of this longitudinal study is to examine the variability in phenotypic expression of the ε4 allele in 
elders who were cognitively intact at study entry. Over the course of the 5-year interval, a subset of ε4 carriers experienced 
a decline in cognitive status (“ε4+ declining”). We hypothesized that the ε4+ declining group would experience greater 
volumetric changes as measured by structural MRI than ε4 carriers who experienced no meaningful changes in cognitive 
performance over the 5-year interval (“ε4+ stable”) and ε4 noncarriers (“ε4−”). A previous study conducted on this sample 
(Reiter et al., 2016) identified differences in longitudinal changes in hippocampal volume, global gray matter volume, and 
ventricular size between ε4 carriers and noncarriers. The present study focused on differences in the rate of volumetric 
change in these anatomical regions between stable and declining ε4 carriers and noncarriers. 
Method 
Participants 
Healthy, cognitively intact older adults, ages 65–85, were recruited as part of a 5-year longitudinal study (Rao et al., 
2015; Seidenberg et al., 2009) via newspaper advertisements and a telephone screen. An in-person study visit 
involved APOE genotyping based on a polymerase chain reaction method and administration of a cognitive screening 
battery to determine if the potential participant was cognitively intact. This battery consisted of the Mini Mental State 
Exam (MMSE; Folstein, Folstein, & McHugh, 1975), Dementia Rating Scale 2 (DRS-2; Jurica, Leitten, & Mattis, 2001), and Rey 
Auditory Verbal Learning Test (RAVLT; Rey, 1958). Criteria used to define intact cognition in this study have been previously 
reported (Seidenberg et al., 2009). All protocols, in full compliance with American Psychological Association ethical 
standards, were approved by the local institutional review board, and participants received compensation. A total of 72 
participants were tested at baseline (T1) with all measures for the current study. Only the 48 participants who returned for 
both neuropsychological and structural MRI follow-up sessions (1.5 years [T2] and 5 years [T3]) were included in the current 
study. On this basis, the study attrition rate over 5 years was 33%; three participants had T1 and T3 data but were missing 
T2 (all were ε4+), and 21 participants (13 ε4+) had T1 and T2 data but were not scanned at T3 due to health decline (6), 
deceased (5), lost to follow-up (3), refused scan (3), moved away (3), and no longer safe to be scanned (1). No group 
differences were observed in attrition rates at each of the two follow-up scan sessions. 
 
The 48 participants were subdivided by APOE ε4 allele inheritance: 26 ε4 carriers (ε4+) and 22 ε4 noncarriers (ε4−). The ε4 
carrier group was further subdivided based on changes in cognitive status over the 5-year study interval. The ε4+ 
participants were defined as “declining” if a reduction from baseline performance of at least one standard deviation (SD) 
was observed on at least one of the three principal outcome indices (Woodard et al., 2010). Using these criteria, 15 ε4+ 




Table 1. Baseline Characteristics by Gene and Cognitive Decline Status 
Variable E4- (n = 22) E4+ stable (n = 11) E4+ declining (n = 15) p value Effect size 
Age (years) 73.1 (5.2) 71.9 (4.3) 73.0 (4.3) .77 .01a 
Sex (n, % female) 18, 82% 9, 82% 12, 80% .99 .02b 
Education (years) 14.0 (1.8) 16.8 (3.2) 14.8 (3.1) .02 .17a 
Family history (n, % yes) 0, 0% 7, 64% 12, 80% .35 .35b 
Note.    Values are presented as means with standard deviations in parentheses unless otherwise noted. Bolded values are 
statistically significant at p < .05. E4- = E4 noncarriers; E4+ stable = E4 carriers who remained cognitively stable over 5 
years; E4+ declining = E4 carriers who cognitively declined over 5 years. 
a Partial eta squared. b Cramèr’s V. 
 
No significant differences were observed between the three groups for mean age in years (ε4−: 73.1 years, SD = 5.2; ε4+ 
stable: 71.9 years, SD = 4.3; ε4+ declining: 73.0 years, SD = 4.3; p = .768, ηp2 = 0.012; 95% CIs [71.1, 75.1], [69.0, 74.7], and 
[70.5, 75.4]) or for number of females (ε4−: 18, 82%; ε4+ stable: 9, 82%; ε4+ declining: 12, 80%; p = .989, Cramèr’s V = 
0.022). However, significant group differences, F(2, 45) = 4.45, p = .017, ηp2 = 0.165, were observed for mean years of 
education (ε4−: 14.0 years, SD = 1.8; ε4+ stable: 16.8 years, SD = 3.2; ε4+ declining: 14.8 years, SD = 3.1; 95% CIs [12.8, 
15.1], [15.2, 18.4], and [13.4, 16.2]), with the ε4+ stable group being significantly more educated than the ε4− group. No 
significant baseline group differences were observed on the MMSE, DRS-2, or RAVLT, although group differences were 




Table 2. Cognitive Performances by Group Across Time 




Baseline      
MMSE 29.3 (0.8) 29.6 (0.8) 28.9 (1.0) .23 .06 
DRS-2 Total 141.1 (2.0) 140.6 (1.6) 140.1 (4.4) .55 .03 
RAVLT Total Trials 49.2 (8.2) 51.7 (7.7) 46.9 (8.0) .32 .05 
RAVLT DR 9.8 (2.1) 10.7 (3.1) 9.1 (2.8) .31 .05 
18 months      
MMSE 29.7 (0.5) 29.3 (0.9) 29.5 (0.8) .35 .05 
DRS-2 Total 139.0 (2.8) 138.9 (2.1) 138.3 (3.5) .81 .01 
RAVLT Total Trials 47.5 (7.6) 54.6 (6.0) 40.4 (7.6) <.01 .34 
RAVLT DR 9.4 (2.6) 11.8 (2.7) 5.8 (2.0) <.01 .47 
5 years      
MMSE 29.7 (0.7) 29.4 (0.7) 28.3 (2.7) .07 .13 
DRS-2 Total 141.7 (2.2) 141.3 (1.9) 138.9 (6.1) .11 .11 
RAVLT Total Trials 48.5 (7.5) 50.6 (6.4) 42.7 (13.5) .13 .10 
RAVLT DR 10.0 (2.5) 11.1 (2.0) 6.2 (4.2) <.01 .31 
Note.    Values are presented as means with standard deviations in parentheses. Bolded values are statistically significant  
at p < .05.  Effect  sizes  are  partial  eta  squared  values.  Sample  sizes  at  baseline: E4- = 22, E4+ stable = 11, E4+ 
declining = 15; sample sizes at 18 months: E4- = 22, E4+ stable = 11, E4+ declining = 15;  sample  sizes  at  5  years:  E4- 
= 20,  E4+ stable  = 9,  E4+ declining  = 13.  E4- = E4  noncarriers;  E4+ stable = E4 carriers who remained cognitively 
stable over 5 years; E4+ declining = E4 carriers who cognitively declined over 5 years. MMSE = Mini Mental State Exam; 
DRS-2 = Dementia Rating Scale–Second Edition; RAVLT = Rey Auditory Verbal Learning Test; DR = Delayed Recall. 
 
There were no significant group differences in the number of months between T1 and T2 (ε4−: 18.5 months, SD = 1.7; ε4+ 
stable: 18.2 months, SD = 0.6; ε4+ declining: 18.3 months, SD = 0.8; p = .761, ηp2 = 0.012; 95% CIs [18.0, 19.1], [17.4, 19.0], 
and [17.7, 19.0]) or between T1 and T3 (ε4−: 59.0 months, SD = 2.6; ε4+ stable: 58.2 months, SD = 4.5; ε4+ declining: 56.8 
months, SD = 4.4; p = .2091, ηp2 = 0.067; 95% CIs [57.4, 60.6], [55.9, 60.4], and [54.9, 57.7]). 
 
MRI Acquisition and Processing 
High-resolution, three-dimensional spoiled gradient-recalled at steady-state (SPGR) anatomic images were acquired on a 
General Electric (Waukesha, WI) Signa Excite 3.0 Tesla short bore scanner equipped with a quad split quadrature 
transmit/receive head coil (Echo time [TE] = 3.9 ms; repetition time [TR] = 9.5 ms; inversion recovery [IR] preparation time = 
450 ms; flip angle = 12°; number of excitations [NEX] = 2; slice thickness = 1.0 mm; field of view [FOV] = 24 cm; resolution = 
256 × 224). A scanner upgrade took place near the end of the final retest period. Two ε4+ participants and one ε4− 
participant had their third scan conducted on a GE MR750 3.0 Tesla scanner (TE = 3.9 ms; TR = 9.6 ms; IR preparation time = 
450 ms; flip angle = 12°; NEX = 1; slice thickness = 1.0 mm; FOV = 24 cm; resolution = 256 × 224). A between-scanner 
comparison showed no systematic differences. Whole-brain and regional volumes were derived from T1-weighted SPGR 
images using the longitudinal stream in Freesurfer v.5.1 software (Fischl et al., 2002). A previous study (Reiter et al., 2016) 
demonstrated longitudinal differences between ε4+ and ε4− participants primarily in volumes of the hippocampus, inferior 
lateral and lateral ventricles, and cortical gray matter. To minimize multiple comparisons, we confined the analysis to 
determine the effect of cognitive decline within the ε4+ group to eight bilateral brain volumes: hippocampi, inferior lateral 
ventricles, lateral ventricles, and cortical gray matter. 
 
Statistical Analyses 
All brain volumes were converted to residualized z scores controlling for intracranial volume and age at baseline. 
Longitudinal linear mixed-effects (LME) models were used to examine the effects of group and time on anatomical brain 
volumes (Rao et al., 2015; Reiter et al., 2016). Time was based on the number of days from T1. For our LME models, the ε4− 
group served as the reference group. Although years of education differed between groups (see above), education did not 
significantly correlate with any of the volumetric measurements; as a result, education was not used as a covariate in the 
LME analyses. To control for inflated Type I error rate due to multiple comparisons, false discovery rate (FDR) correction 
procedures were applied to all LME analyses. 
Results 
Table 3 summarizes the results of the LME analyses applied to bilateral volumes derived from the hippocampi, cortical gray 
matter, lateral ventricles, and inferior lateral ventricles. There were no significant baseline differences between groups for 
all eight brain volumes. Over the 5-year follow-up interval, the ε4+ declining group had significantly more atrophy than the 
ε4− group in the left (p = .001, Cohen’s d = .691) and right (p = .003, d = .622) cortical gray matter volumes and in the left 
(p = .003, d = .625) and right (p = .020, d = .492) hippocampi. The ε4+ declining group also had significantly greater 
expansion of the right inferior lateral ventricle than the ε4− group over the 5-year interval (p < .001, d = .751). These 
findings reflect medium to large effect sizes. Figure 1 displays regression lines depicting baseline and predicted annualized 
rates of change in volumes (in standard score units, adjusted for age and intracranial volume) over the 5-year study period 





Table 3 Predicted Annual Brain Volume Change Over 5 Years by APOE ϵ4 and Cognitive Decline Status 
 
  Intercept 
(baseline) 





4 a  
 
v. 4 stableb 4 decliningb v. 4 c  v. 4 stabled  v. 4 
decliningd 
Left hemisphere       
Lateral ventricle -.101 
(.199) 




.008 (.017) .022 (.016) 




.025 (.033) .062 (.030) 
Hippocampus .190 (.204) -.154 (.353) -.160 
(.321) 
.018 (.017) -.025 
(.031) 
-.085 (.028) 
Cortical gray matter 
volume 
.045 (.210) -.202 (.364) .380 (.330) .020 (.020) -.014 
(.036) 
-.109 (.033) 
Right hemisphere       
Lateral ventricle -.135 
(.209) 





Inferior lateral ventricle -.099 
(.186) 




.018 (.036) .121 (.033) 
Hippocampus .311 (.200) -.486 (.346) -.565 
(.314) 
.025 (.019) .007 (.033) -.072 (.030) 
Cortical gray matter 
volume 






Figure 1. Regression lines depicting baseline and predicted annualized rates of change in volumes (in standard score units, 
adjusted for age and intracranial volume) over the 5-year study period by group. ε4− = ε4 noncarrier; ε4+ stable = 
cognitively stable ε4 carrier; ε4+ declining = cognitively declining ε4 carrier; L = left; R = right. 
 
In a direct comparison of the two ε4+ groups, the ε4+ declining group exhibited significantly greater atrophy of the right 
hippocampus (p = .030, d = .457) and left cortical gray matter (p = .017, d = .506) and expansion of the right inferior lateral 
ventricle (p = .011, d = .541) than the ε4+ stable group over the 5-year interval. These findings reflect medium effect sizes. 
However, these three interaction effects did not survive FDR correction likely due to the small sample size. 
Discussion 
Results confirmed our hypothesis that the ε4 group that exhibited a decline in verbal episodic memory and global cognitive 
function over the 5-year retest interval exhibited greater brain atrophy than ε4 noncarriers. In contrast, ε4 carriers who 
experienced no significant 5-year changes in memory and cognitive test performance exhibited atrophy rates comparable 
to ε4 noncarriers. The greater atrophy rates in the ε4+ declining group occurred bilaterally in the hippocampi and global 
gray matter and in the right inferior lateral ventricle. Importantly, the three groups showed no differences in brain volumes 
at the baseline examination. Furthermore, all participants were cognitively intact at enrollment as an entry criterion and did 
not differ from each other on measures of episodic memory or global cognition at baseline. 
 
ε4 carriers exhibit significantly greater rates of hippocampal and cortical gray matter atrophy and ventricular enlargement 
than ε4 noncarriers (Reiter et al., 2016). Results from the current study indicate that these group differences may be driven 
by a subset of ε4 carriers who exhibited cognitive decline over the 5-year retest interval. This study demonstrates the 
correspondence between longitudinal changes in cognition and brain volumes in a subgroup of ε4 carriers, a finding that 
has not previously received significant attention in the literature. 
 
Whereas possession of the ε4 allele increases risk of AD, not all ε4 carriers demonstrate AD-related neurodegeneration 
during their life span (Relkin et al., 1996). Given the increasing risk of AD with increasing age (Hebert et al., 1995), it is 
conceivable that a longer follow-up interval would be needed to see such changes in our stable ε4 carriers. However, our 
ε4+ declining and stable groups did not differ in mean age. There are also data to suggest that the increased risk of 
developing AD in the presence of the ε4 allele diminishes after the age of 80 (Breitner et al., 1999). Thus, it is unlikely that 
the group differences are simply related to the length of the follow-up interval. 
 
There are several physiological pathways whereby the ε4 allele may exert deleterious effects that lead to 
neurodegeneration and contribute to loss of cognitive function. The apoE4 isoform expressed by the ε4 allele preferentially 
binds to low-density lipoprotein receptors, resulting in wide-ranging effects on lipid and cholesterol metabolism, including 
increased production of very low-density lipoproteins, the release of proinflammatory cytokines, and atherosclerosis 
(Zhang, Wu, & Wu, 2011). In nervous tissue, apoE4 is associated with decreased lipoprotein lipase activity and decreased 
delivery of free fatty acids to brain cells, leading to altered lipid membrane homeostasis, decreased cerebral glucose 
metabolism, and increased glial activation and inflammation; it impairs the processing and removal of extracellular amyloid-
beta peptide, increases the phosphorylation of tau, and impairs cholinergic function (Lane & Farlow, 2005). Collectively, 
these processes (among others) may lead to neuronal cell dysfunction and apoptotic processes, leading to cell death. 
However, susceptibility to the effects of the APOE ε4 allele on peripheral and brain lipid metabolism, and ultimately on 
brain structure and function, varies considerably in the population. 
 
What other factors might influence the variability in the phenotypic expression of the ε4 allele? Physically active ε4 carriers 
experience significantly less hippocampal atrophy over time compared to inactive ε4 carriers (Smith et al., 2014). Similarly, 
physically active ε4 carriers experience increased memory-related brain activation (Smith et al., 2011) and reduced 
neurodegeneration of white matter fiber populations within projection and association tracts (Smith et al., 2016) compared 
to sedentary ε4 carriers. Importantly, these brain imaging differences were not observed in noncarriers, suggesting that 
physical activity has a specific neuroprotective effect in ε4 carriers. Moreover, we previously reported that physically 
inactive ε4 carriers have a greater probability of cognitive decline over 18 months compared to physically active ε4 carriers 
(Woodard et al., 2012). In addition, Schreiber and colleagues (2016) found that low vascular risk and lifetime engagement in 
stimulating cognitive activities served to preserve cognitive abilities in healthy ε4 carriers. Schwartz and colleagues 
(2016) speculate that greater brain structural integrity, high socioeconomic status, lack of brain injury, high occupational 
achievement, and perseverance, all indicators of enhanced brain and cognitive reserve, may moderate the effect of the ε4 
allele on cognitive decline. Of note, level of educational attainment, an important indicator of cognitive reserve, was 2.0 
years greater in the ε4+ stable group than in the ε4+ declining group, although this difference was not significant. 
 
Other possible explanations involve ε4 allele dose and family history of AD. Martins, Oulhaj, de Jager, and Williams 
(2005) found that ε4 homozygotes displayed a greater rate of cognitive decline than ε4 heterozygotes over a 3-year 
interval. Our results are unlikely to be influenced by this factor because only two of our ε4 carriers were homozygotes 
(ε4/ε4), and both were in the cognitively stable group. Family history of AD has also been examined as an additional risk 
factor for cognitive decline and neurodegeneration in ε4 carriers. Donix and colleagues (2010) found that family history of 
AD explained more variance in cortical thickness than APOE ε4 status. Family history is unlikely to have influenced our 
results because there were no statistically significant group differences in family history of AD between the ε4+ stable (64%) 
and ε4+ declining (80%) groups (p = .35). 
 
The ε4+ declining group had significantly greater expansion of the right inferior lateral ventricle than the ε4− group. In 
contrast, there were no significant group differences in the volume of the main body of the lateral ventricles. In the absence 
of hydrocephalus, increased ventricular volume is an indirect estimate of atrophy within periventricular structures (Tang et 
al., 2015). Not surprisingly, as the hippocampus and other medial temporal lobe structures decrease in volume, the inferior 
horns of the lateral ventricles expand (Thompson et al., 2004), which our results appear to typify. 
 
A limitation of this study is the small sample size. Nevertheless, we found medium to large effect sizes in the right inferior 
lateral ventricle, hippocampi, and cortical gray matter regions. A further limitation, relevant to all longitudinal studies, was 
attrition. The participants who were missing data at one of the three sessions were excluded from the study. There were no 
group differences between included and excluded participants at either time point in age, education, or family history and 
no baseline test score differences between those included or excluded at T2. However, despite all having intact scores at 
baseline, those unable to be scanned at T3 (Year 5) were more likely to be male (p = .036) and had lower baseline scores on 
the DRS-2 total (p = .003) and RAVLT total trials (p = .012). Notably, all three participants who missed T2 were ε4+, and 13 of 
21 who missed T3 were ε4+. Thus, inclusion of these missing participants would likely have strengthened the present 
findings. 
 
Another limitation of this study is the absence of data on AD-specific biomarkers, such as can be derived from cerebrospinal 
fluid analyses of tau and amyloid proteins or positron emission tomography imaging of amyloid deposition. Lim and 
colleagues (2013) found that Aβ amyloid burden explained 14% of the variance in episodic memory performance in ε4 
carriers but had no relationship with memory performance in ε4 noncarriers. Another study found that ε4 carriers with high 
Aβ levels had greater declines in verbal memory and global cognition over 1.5 years than ε4 carriers with low Aβ levels 
(Mormino et al., 2014). If these data were available in the current study, we would hypothesize that AD biomarkers would 
be more abnormal in ε4 declining than in ε4 stable carriers. 
 
In conclusion, our study demonstrates that the degree of long-term longitudinal changes in episodic memory and global 
cognition are linked with the severity of changes in brain atrophy in persons who possess the APOE ε4 allele. Thus, this 
study illustrates the variability in phenotypic expression of the ε4 allele, which may be associated with potential lifestyle 
factors, such as physical activity, and cognitive reserve. Larger scale studies are required to examine these potential 
influences as a means for understanding modifiable risk and protective factors associated with genetic risk. 
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